Key Developments: CryoLife Inc (CRY.N)

CRY.N on New York Stock Exchange

9.19USD
10 Jul 2014
Price Change (% chg)

$0.49 (+5.63%)
Prev Close
$8.70
Open
$8.70
Day's High
$9.34
Day's Low
$8.70
Volume
45,818
Avg. Vol
37,265
52-wk High
$12.13
52-wk Low
$6.02

Search Stocks

Latest Key Developments (Source: Significant Developments)

CryoLife Inc Reaffirms FY 2013 Revenue Guidance; Raises FY 2013 EPS Guidance
Tuesday, 29 Oct 2013 08:04am EDT 

CryoLife Inc announced that for fiscal 2013, it expects total revenue to be in the range of $139 million-$141 million, remains unchanged from announced previously and earnings per share (EPS) to be in the range of $0.58-$0.60, as compared to previous range of $0.24-$0.27. According to I/B/E/S Estimates, analysts on an average were expecting the Company to report revenue of $139 million and EPS of $0.36 for fiscal 2013.  Full Article

CryoLife Inc To Receive Approximately $15.1 Million From Acquisition Of Medafor, Inc. By C. R. Bard, Inc.
Monday, 7 Oct 2013 08:34am EDT 

CryoLife Inc announced that it expects to receive an initial payment of approximately $15.1 million for its 2,379,554 shares of Medafor common stock due to C.R. Bard, Inc.'s acquisition of Medafor, Inc. CryoLife could receive additional payments of up to $8.4 million upon the release of funds held in escrow and the satisfaction of certain contingent milestones. CryoLife's carrying basis for the 2,379,554 shares of Medafor common stock was approximately $2.6 million.  Full Article

CryoLife Inc Announces Quarterly Cash Dividend
Wednesday, 21 Aug 2013 08:34am EDT 

CryoLife Inc announced that its Board of Directors has approved a quarterly cash dividend for the third quarter 2013 of $0.0275 per share of common stock outstanding. The quarterly cash dividend of $0.0275 per share will be paid on September 20, 2013 to all common stockholders of record as of September 13, 2013. The ex-dividend date for the quarterly dividend is September 11, 2013.  Full Article

CryoLife Inc Lowers High End Of Prior FY 2013 Revenue Guidance To A Range In Line With Analysts' Estimates; Lowers FY 2013 EPS Guidance
Thursday, 25 Jul 2013 08:04am EDT 

CryoLife Inc announced that for fiscal 2013, it expects revenue to be in the range of $139 million-$141 million from the previous range of $139 million-$143 million, earnings per share (EPS) is expected to be in the range of $0.24-$0.27 from the previous range of $0.25-$0.28. According to I/B/E/S Estimates, analysts on an average were expecting the Company to report revenue of $141 million and EPS of $0.28 for fiscal 2013.  Full Article

CryoLife Inc Receives Conditional IDE Approval To Begin Clinical Trials For PerClot In The U.S.
Wednesday, 19 Jun 2013 08:34am EDT 

CryoLife Inc announced that it has received conditional approval of its Investigational Device Exemption (IDE) for PerClot from the United States Food and Drug Administration (FDA). PerClot is a unique hemostat composed of absorbable polysaccharide granules and is intended for use in surgical procedures as an adjunctive hemostatic device when control of capillary, venular, and arteriolar bleeding by pressure, ligature, and other conventional means is ineffective or impractical. PerClot has CE Mark designation and CryoLife began distributing PerClot in several international markets in the fourth quarter of 2010.  Full Article

CryoLife Inc Receives CE Mark For HeRo Graft
Monday, 10 Jun 2013 08:34am EDT 

CryoLife, Inc. announced that achievement of a CE (Conformite Europeenne) Mark for the HeRO (Hemodialysis Reliable Outflow) Graft system produced at the Company's new manufacturing facility in Atlanta. The HeRO Graft is a proprietary graft-based solution for end-stage renal disease (ESRD) hemodialysis patients with limited access options and central venous stenosis.  Full Article

CryoLife Inc Increases Quarterly Cash Dividend 10% For Second Quarter 2013
Tuesday, 28 May 2013 08:55am EDT 

CryoLife Inc announced that its Board of Directors has approved a 10% increase in the quarterly cash dividend for the second quarter 2013 from $0.025 to $0.0275 per share of common stock outstanding. The quarterly cash dividend of $0.0275 per share will be paid on June 21, 2013 to all common stockholders of record as of June 14, 2013. The ex-dividend date for the quarterly dividend is June 12, 2013.  Full Article

CryoLife Inc Reaffirms FY 2013 Guidance-Conference Call
Saturday, 20 Apr 2013 02:00pm EDT 

CryoLife Inc reaffirmed fiscal 2013 guidance and expects revenues to be between $139 million and $143 million and expect earnings per share (EPS) for fiscal 2013 to be between $0.25 and $0.28. According to I/B/E/S Estimates, analysts on an average were expecting the Company to report revenue of $142 million and EPS of $0.27 for fiscal 2013.  Full Article

CryoLife Inc Receives FDA Clearance For Next Generation HeRO Device
Thursday, 4 Apr 2013 08:34am EDT 

CryoLife Inc announced that it has received U.S. Food and Drug Administration (FDA) 510(k) clearance for a next generation HeRO (Hemodialysis Reliable Outflow) device. The HeRO device is the subcutaneous AV access solution clinically proven to maintain long-term access for end-stage renal disease (ERSD) hemodialysis patients with central venous stenosis. CryoLife anticipates launching the next generation HeRO device during the fourth quarter of 2013 following scale up and validation of the manufacturing process. The current generation includes a standard ePTFE graft, which requires the placement of a temporary dialysis catheter for approximately 2-3 weeks until the graft incorporates into the surrounding tissue and can be used for hemodialysis access. By design, early access grafts allow access in a matter of days, thus eliminating the need for an accompanying dialysis catheter.  Full Article

CryoLife Inc Expands Stock Repurchase Program
Thursday, 14 Feb 2013 08:26am EST 

CryoLife Inc announced that its Board of Directors authorized the Company's purchase of $15 million of its common stock through October 31, 2014. Under this program, the purchase of shares can be made from time to time in the open market or through privately negotiated transactions on such terms as management deems appropriate, and will be dependent upon various factors, including price, regulatory requirements and other market conditions. The Company may enter into agreements from time to time that provide for common stock repurchases during Company announced "blackout periods of such securities in compliance with Rule 10b5-1 promulgated under the Securities Exchange Act of 1934. Pursuant to its credit facility the Company is entitled to repurchase up to approximately $10.2 million of its common stock without obtaining lender's consent.  Full Article

Search Stocks